Stifel Financial Corp trimmed its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 17.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 568,012 shares of the company’s stock after selling 116,495 shares during the quarter. Stifel Financial Corp owned about 0.06% of Teva Pharmaceutical Industries worth $10,022,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. San Francisco Sentry Investment Group CA acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $106,000. Bronfman E.L. Rothschild L.P. grew its position in shares of Teva Pharmaceutical Industries by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares during the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the third quarter valued at about $129,000. Shelter Mutual Insurance Co acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $133,000. Finally, Fayez Sarofim & Co. acquired a new stake in shares of Teva Pharmaceutical Industries in the second quarter valued at about $204,000. 52.05% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) traded down $0.05 on Tuesday, reaching $16.39. 17,329,042 shares of the company’s stock were exchanged, compared to its average volume of 15,790,248. The company has a market capitalization of $16,316.96, a PE ratio of 3.71 and a beta of 0.55. The company has a current ratio of 0.96, a quick ratio of 0.66 and a debt-to-equity ratio of 1.20. Teva Pharmaceutical Industries Limited has a 1 year low of $10.85 and a 1 year high of $38.31.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share. This represents a $0.34 dividend on an annualized basis and a yield of 2.07%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio is -12.10%.

Several equities research analysts have recently issued reports on the company. Guggenheim assumed coverage on Teva Pharmaceutical Industries in a research report on Tuesday. They issued a “neutral” rating and a $16.00 price target on the stock. ValuEngine raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research report on Tuesday, December 5th. Royal Bank of Canada set a $11.00 price target on Teva Pharmaceutical Industries and gave the company a “sell” rating in a research report on Wednesday, November 29th. Mizuho raised their price target on Teva Pharmaceutical Industries from $12.00 to $16.00 and gave the company a “neutral” rating in a research report on Wednesday, November 29th. Finally, BTIG Research set a $16.00 price target on Teva Pharmaceutical Industries and gave the company a “buy” rating in a research report on Tuesday, November 28th. Seven investment analysts have rated the stock with a sell rating, eighteen have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $19.18.

ILLEGAL ACTIVITY WARNING: “Stifel Financial Corp Has $10.02 Million Holdings in Teva Pharmaceutical Industries Limited (TEVA)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/12/12/stifel-financial-corp-has-10-02-million-holdings-in-teva-pharmaceutical-industries-limited-teva.html.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related stocks with our FREE daily email newsletter.